论文部分内容阅读
目的:探讨131I照射以及联合PARP-1抑制剂(PJ-34)对于甲状腺癌细胞系BCPAP增殖与凋亡的影响。方法:常规培养人甲状腺癌细胞BCPAP,采用CCK-8法检测BCPAP的增殖、流式细胞术检测细胞凋亡,并用Western blot法检测Bcl-2、Bax的表达。结果:131I和PJ-34均能抑制BCPAP细胞的增殖,且与浓度呈相关性,而且两者联合作用比单独应用131I有更好的抑制效果。流式细胞术检测结果显示131I和PJ-34的联合作用比单独用131I有更高的凋亡率。Western blot结果显示随着131I中加入的PJ-34浓度的升高,Bax表达量逐渐升高,而Bcl-2的表达量呈降低趋势。结论:131I和PJ-34联合作用比单独应用131I对BCPAP有更好的抑制效果和更强的促凋亡作用,这为131I和PJ-34联合治疗甲状腺癌提供了初步的实验依据。
Objective: To investigate the effects of 131I irradiation and PARP-1 inhibitor (PJ-34) on proliferation and apoptosis of BCPAP in thyroid cancer cell line. Methods: BCPAP was routinely cultured in human thyroid carcinoma cells. The proliferation of BCPAP was detected by CCK-8 assay. Apoptosis was detected by flow cytometry. The expression of Bcl-2 and Bax was detected by Western blot. Results: Both 131I and PJ-34 could inhibit the proliferation of BCPAP cells in a concentration-dependent manner, and the combined effects of 131I and PJ-34 were better than that of 131I alone. Flow cytometry results showed that the combined effect of 131I and PJ-34 had a higher apoptosis rate than that of 131I alone. Western blot results showed that with the increase of PJ-34 concentration in 131I, the expression of Bax gradually increased while the expression of Bcl-2 decreased. Conclusion: The combined effect of 131I and PJ-34 is better than 131I alone in inhibiting BCPAP and promoting apoptosis. This provides a preliminary experimental evidence for 131I and PJ-34 combined treatment of thyroid cancer.